Source: Virtual Congress 2021 – COVID - 19 biomarkers



Rating:

Share or cite this content

Citations should be made in the following way:
I. Mejri Ep Ajili (Tunis, Tunisia), N. Boubaker (Tunis, Tunisia), H. Kchouk (Tunis, Tunisia), S. Mhamdi (Tunis, Tunisia), S. Daboussi (Tunis, Tunisia), C. Aichaouia (Tunis, Tunisia), Z. Moatemri (Tunis, Tunisia), M. Khadhraoui (Tunis, Tunisia). The prognostic value of procalcitonin in patients with hypoxemic COVID 19 pneumonia.. 658

Member's Comments

No comment yet.

Related content which might interest you: Determining the prognostic value of procalcitonin in ICU patients who developed hospital acquired pneumonia and comparing with sencitive CRP Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009 Diagnostic and prognostic value of C-reactive protein in community-acquired pneumonia hospitalized patients Source: Eur Respir J 2004; 24: Suppl. 48, 188s Year: 2004 Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 The assessment of prognostic rules in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 149s Year: 2003 Proadrenomedullin (proADM) for clinical severity and prognosis in patients with pneumonia Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017 Correlation of procalcitonin and CRP in community-acquired pneumonia with CRB-65 score and prognosis – results from the German competence network CAPNETZ Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Calprotectin as a biomarker of pneumonia in patients hospitalized with AECOPD Source: International Congress 2019 – Airway infection in COPD Year: 2019 Incidence of ventilator associated pneumonia (VAP) and assessment of serial estimation of procalcitonin levels as a prognostic marker in cases of VAP in a tertiary centre in India Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections Year: 2012 Prognostic evaluation of COPD patients with pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 257s Year: 2005 Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 Pro-adrenomedullin, procalcitonin and CRP levels to predict bacterial pneumonia in patients admitted to emergency room Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Predictive value of procalcitonin in ventilator-associated pneumonia Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Pro-adrenomedullin as prognostic marker in patients with CAP Source: Annual Congress 2008 - Improved diagnosis and clinical decision-making by integrating information from new biomarkers Year: 2008 The diagnostic value of serum procalcitonin in differential diagnosis of pulmonary embolism and pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 462s Year: 2007